Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Neubauer

Showing results (191-200 of 224) with videos related to

Pageof 23
Sort By:
Haematologica|August 16, 2019
<i>EZH2</i> mutations and impact on clinical outcome: an analysis in 1,604 patients with newly diagnosed acute myeloid leukemiaSebastian Stasik, Jan M Middeke, Michael Kramer, et al.
European Journal of Haematology|October 14, 2024
Impact of TP53 Mutation Status in Elderly AML Patients When Adding All-Trans Retinoic Acid or Valproic Acid to DecitabineHelena Bresser, Claudia Schmoor, Olga Grishina, et al.
Blood Cancer Journal|May 26, 2023
UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcomeJulia-Annabell Georgi, Sebastian Stasik, Jan-Niklas Eckardt, et al.
Blood Cancer Journal|January 24, 2023
Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcomeJan-Niklas Eckardt, Sebastian Stasik, Christoph Röllig, et al.
Blood Advances|August 30, 2021
Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemiaSebastian Stasik, Jan-Niklas Eckardt, Michael Kramer, et al.
The Lancet. Haematology|November 1, 2023
10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trialMichael Lübbert, Pierre W Wijermans, Michal Kicinski, et al.
Cancers|April 30, 2021
Loss-of-Function Mutations of <i>BCOR</i> Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid LeukemiaJan-Niklas Eckardt, Sebastian Stasik, Michael Kramer, et al.
Haematologica|April 24, 2024
Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimensDavid Baden, Sven Zukunft, Gema Hernandez, et al.
Leukemia|October 13, 2023
Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemiaJan-Niklas Eckardt, Sebastian Stasik, Christoph Röllig, et al.
Cancer Genetics|April 8, 2026
Optimized precision oncology through implementation of a comprehensive molecular analysis pipeline - relevance for additional therapeutic optionsNuwar Harb, Marcel Romey, Albert Grass, et al.
Pageof 23

Showing results (191-200 of 224) with videos related to

Sort By:
Pageof 23
Haematologica|August 16, 2019
<i>EZH2</i> mutations and impact on clinical outcome: an analysis in 1,604 patients with newly diagnosed acute myeloid leukemiaSebastian Stasik, Jan M Middeke, Michael Kramer, et al.
European Journal of Haematology|October 14, 2024
Impact of TP53 Mutation Status in Elderly AML Patients When Adding All-Trans Retinoic Acid or Valproic Acid to DecitabineHelena Bresser, Claudia Schmoor, Olga Grishina, et al.
Blood Cancer Journal|May 26, 2023
UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcomeJulia-Annabell Georgi, Sebastian Stasik, Jan-Niklas Eckardt, et al.
Blood Cancer Journal|January 24, 2023
Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcomeJan-Niklas Eckardt, Sebastian Stasik, Christoph Röllig, et al.
Blood Advances|August 30, 2021
Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemiaSebastian Stasik, Jan-Niklas Eckardt, Michael Kramer, et al.
The Lancet. Haematology|November 1, 2023
10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trialMichael Lübbert, Pierre W Wijermans, Michal Kicinski, et al.
Cancers|April 30, 2021
Loss-of-Function Mutations of <i>BCOR</i> Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid LeukemiaJan-Niklas Eckardt, Sebastian Stasik, Michael Kramer, et al.
Haematologica|April 24, 2024
Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimensDavid Baden, Sven Zukunft, Gema Hernandez, et al.
Leukemia|October 13, 2023
Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemiaJan-Niklas Eckardt, Sebastian Stasik, Christoph Röllig, et al.
Cancer Genetics|April 8, 2026
Optimized precision oncology through implementation of a comprehensive molecular analysis pipeline - relevance for additional therapeutic optionsNuwar Harb, Marcel Romey, Albert Grass, et al.
Pageof 23